Company news
Luye Pharma Group Ltd. news
Latest news releases, newest first. Pick a year for every news release, call and deck from that year.
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
October 7, 2026
Interim Report 2026
September 29, 2026
Luye Pharma Announces 2026 Interim Results
September 1, 2026
Luye Pharma Announces Successful Completion of a U.S. Bridging Clinical Trial of Its Innovative Drug LY03015 (VMAT2 Inhibitor/Sigma-1R...
August 5, 2026
Luye Pharma Announces Positive Phase 2 Results of LY03015, a VMAT2 Inhibitor and Sigma-1R Agonist, for Tardive Dyskinesia in China
June 16, 2026
Luye Pharma Announces First Subject Enrolled in U.S. PK Bridging Clinical Trial of Its VMAT2 Inhibitor/Sigma-1R Agonist LY03015
April 21, 2026
First Subject Enrolled in Phase Ⅱ Clinical Trial of Luye Pharma’s TAAR1/5-HT2CR-targeted Investigational Drug for Treating...
April 8, 2026
NMPA Accepts the NDA for Luye Pharma’s Ruoxinlin® for the New Indication of Generalized Anxiety Disorder
January 8, 2026
Luye Pharma Receives FDA Clearance of IND Application for Its Next-generation 5-HT2AR Inverse Agonist/5-HT2CR Antagonist LY03017
November 24, 2025
Luye Pharma Announces 2025 Half-Year Results
August 29, 2025
All Patients Enrolled for the Phase III Clinical Trial of Luye Pharma’s Ruoxinlin® for Treating Generalized Anxiety Disorder
August 18, 2025
First Subject Enrolled in Phase 1 Clinical Trial for Luye Pharma's Investigational Antidepressant Targeting NET/DAT/GABAAR
August 3, 2025
Luye Pharma Launches Its Transdermal Patch Rotigotine Luye in the UK for the Treatment of Parkinson’s Disease and Restless Legs Syndrome
April 10, 2025
Luye Pharma Announces U.S. Launch of ERZOFRI® (paliperidone palmitate) Extended-Release Injectable Suspension for the Treatment of...
April 6, 2025
Dual TAAR1/5-HT2CR Agonist LY03020 Approved for Clinical Trials in the U.S.
January 15, 2025
Class 1 Innovative Antidepressant Targeting NET/DAT/GABAAR Approved for Clinical Trials in China
November 11, 2024
Luye Pharma Announces 2024 Half Year Results
August 29, 2024
Luye Pharma mRNA-based Therapeutic HPV Vaccine LY01620 Approved for Clinical Trials in China
August 13, 2024
Dual TAAR1/5-HT2CR Agonist LY03020 Approved for Clinical Trials in China
August 5, 2024
Luye Pharma Announces U.S. FDA Approval of ERZOFRI® (paliperidone palmitate) Extended-Release Injectable Suspension for Treating...
July 28, 2024
Luye Pharma Will Receive RMB 1.6 Billion Strategic Investment for Shenzhen Luye
July 23, 2024
Analgesic Drug Mimeixin (Oxycodone Hydrochloride and Naloxone Hydrochloride Sustained-Release Tablets) Approved for...
July 4, 2024
Manufacturing Facility for Paliperidone Palmitate Extended-release Injectable Suspension (LY03010) Passes FDA’s PAI...
June 27, 2024
Jinyouping (Rotigotine Microspheres for Injection) Approved for Marketing in China
June 19, 2024
Meibirui (Paliperidone Palmitate Injection) Approved for Marketing in China for Treating Schizophrenia
June 10, 2024
Luye Pharma Announces the Approval of Lurbinectedin for the Treatment of Relapsed Small Cell Lung Cancer in Hong Kong
December 12, 2023
Rivastigmine Twice Weekly Transdermal Patch Approved in China for the Treatment of Alzheimer's Disease
October 31, 2023
The World’s Only Goserelin Microsphere Formulation (Baituowei) Approved in China for the New Indication of Breast Cancer
September 7, 2023
Luye Pharma Announces 2023 Half Year Results
August 30, 2023
Luye Pharma Group: China’s NMPA Accepts and Grants Priority Review Designation to the New Drug Application for Luye Pharma’s Rotigotine Extended-Release...
August 1, 2023
Patient Enrollment Completed for a Phase 2 Clinical Study of Luye Pharma’s Class 1 Analgesic Drug Candidate LY03014
July 6, 2023